Engineering BioChoice Lignin-Based Microparticles for Applications in Veterinary Medicine

BioChoice 木质素基微粒工程在兽医学中的应用

• 批准号: 508318-2017
• 负责人: Allen, Christine
• 金额: $ 1.82万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639969
• 关键词: Engineering; BioChoice; Lignin; Based; Microparticles

Domtar is the largest integrated producer of uncoated free sheet paper in North America. As a result they are amajor producer of lignin, a relatively low value by-product that is used as a solid fuel to generate process steamand power. Lignin, a substance in the cellular walls of plants, is the second most abundant renewable carbonsource on our planet. Domtar has recently produced high-grade USDA Certified bio-based lignin, referred to asBioChoice lignin for potential applications in the energy and chemical industries. For the first time, theproposed research intends to explore Domtar's proprietary BioChoice lignin and derivatives, to be synthesizedthrough this research, for applications in drug delivery. It is expected that this research will result in newintellectual property for Domtar and bring its proprietary material BioChoice into the pharmaceutical realm.Domtar's proprietary BioChoice Kraft lignin is produced from the black liquor of the Plymouth mill at a rate ofabout 50-100 tons per day. While the Plymouth mill was the first commercial demonstration plant, Domtar alsohas 11 other pulp mills, four of which are in Canada. It is Domtar's intention to build out their lignin capacity inmany or all of these facilities as demands and markets grow. Given lignin's low cost, sustainability, resistanceto oxidation, biocompatibility and biodegradability it is of interest for use in biomedical applications. Yet todate, very few studies have explored lignin and its derivatives for applications in drug delivery. The goal of thecurrent research is to synthesize and fully characterize BioChoice lignin-based microparticles that providesustained release of drugs for veterinary applications. The global animal healthcare market, was valued atUS$27.8 billion in 2013 and is expected to reach US$41.9 billion in 2019. New technologies that providecontrolled delivery of drugs for maintenance of good health and treatment of diseases in companion andcommercial animals will further advance this fast growing industry. Growth in this industry in Canada willresult in new opportunities for scientists trained in chemistry as well as pharmaceutical and veterinary sciences.

Domtar是北美最大的未涂层免费纸纸的综合生产商。结果，它们是木质素的Amajor生产商，木质素是一种相对较低的副产品，用作生成工艺蒸汽和蒸汽功率的固体燃料。木质素是植物细胞壁中的一种物质，是我们星球上第二大可再生碳水化合物。 Domtar最近生产了高级USDA认证的基于生物的木质素，该木质素是指对于能源和化学工业中潜在应用的Asbiochoice木质素。这项计划的研究首次旨在探索Domtar专有的生物选择木质素和衍生物，并在这项研究中合成，以用于药物输送。可以预期，这项研究将为Domtar带来新的特性，并将其专有的材料生物选择带入Pharmaceutical M.Tomtar的专有生物选择牛皮纸木质素，是由普利茅斯磨坊（Plymouth Mill of Plymouth Mill）的黑色液体以每天50-100吨的速率生产的。虽然普利茅斯磨坊是第一个商业示范厂，但Domtar也是其他11个纸浆厂，其中四个在加拿大。 Domtar的意图是随着需求和市场的增长，建立其木质素能力Inmany或所有这些设施。鉴于木质素的低成本，可持续性，抗性氧化，生物相容性和生物降解性，在生物医学应用中使用它很感兴趣。然而，很少有研究探讨了木质素及其在药物输送中应用的衍生物。赛车研究的目的是合成并充分表征基于生物选择木质素的微粒，该微粒为兽医应用提供了释放的药物。全球动物医疗保健市场在2013年被估价为278亿美元，预计在2019年将达到419亿美元。新技术提供了提供药物提供的药物来维持良好健康和伴侣和商业疾病的治疗，将进一步发展这一迅速发展的行业。加拿大这个行业的增长将为接受化学培训以及药物和兽医科学培训的科学家提供新的机会。